Addressing Neisseria gonorrhoeae treatment resistance with the DNA gyrase A assay: An economic study, United States.
Targeted antibiotics could delay emergence of resistant Neisseria gonorrhoeae (NG). The DNA gyrase subunit A (gyrA) assay predicts susceptibility to ciprofloxacin. A model found adding a $50 gyrA test for asymptomatic patients screened for NG resulted in cost neutrality. When ciprofloxacin susceptibility was high, a $113 test resulted in savings.